New kidney Drug's journey through the body tracked in tiny trial

NCT ID NCT07284043

Recruiting now Knowledge-focused Sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jan 05, 2026 · Last updated May 22, 2026 · Updated 18 times

Summary

This early-phase study looks at how a new experimental drug called MT1013 is absorbed, broken down, and removed from the body in 6 adults on hemodialysis who have secondary hyperparathyroidism. Participants receive a single dose containing a radioactive tracer so researchers can measure where the drug goes and how it exits the body. The goal is to understand the drug's path, not to treat the condition.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMODIALYSIS SUBJECTS WITH SECONDARY HYPERPARATHYROIDISM are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

The First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital)
RECRUITING

Jinan, Shandong, 250014, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HEMODIALYSIS SUBJECTS WITH SECONDARY HYPERPARATHYROIDISM